Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Scienture Holdings, Inc.
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
25 mars 2025 08h05 HE
|
Scienture Holdings, Inc.
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on...
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
19 mars 2025 08h05 HE
|
Scienture Holdings, Inc.
TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced...
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
18 mars 2025 08h05 HE
|
Scienture Holdings, Inc.
TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced...
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
06 mars 2025 07h40 HE
|
Scienture Holdings, Inc.
TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced...
Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics
21 janv. 2025 08h05 HE
|
Scienture Holdings, Inc.
TAMPA, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a Specialty Pharma company with a novel pipeline of brand products, is pleased to announce the participation of...
Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
17 déc. 2024 08h05 HE
|
Scienture Holdings, Inc.
TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the “Company”) (NASDAQ: SCNX), a specialty pharma company with a novel pipeline of brand products, is pleased to announce its...
Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
10 déc. 2024 08h05 HE
|
Scienture Holdings, Inc.
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC (“the “Company”), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), focused on developing and...
Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement
26 nov. 2024 16h05 HE
|
Scienture Holdings, Inc.
Scienture Holdings to Receive Funding of Up to $12 Million From Private Placement of 10% Secured Convertible Debentures and Up to $50 Million from Equity Line of Credit Tampa, FL, Nov. 26, 2024 ...
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”
24 sept. 2024 08h01 HE
|
Scienture Holdings, Inc.
TRxADE Health, Inc. today announced that it changed its name and ticker symbol to “Scienture Holdings, Inc.” and “SCNX”, respectively, and that the business will continue as a Nasdaq-listed company. ...
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.
20 sept. 2024 11h59 HE
|
Trxade Health, Inc.
TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced...